Dementia Discovery Fund and MRL Ventures Fund led a $36m Series A in Therini Bio, a biotech company, with participation from Merck & Co, Sanofi Ventures, SV Health Investors, Eli Lilly, Alzheimer’s Drug Discovery Foundation and Dolby Family Ventures. "We are thrilled to announce a top-tier investor syndicate, which will allow us to advance our groundbreaking work in developing fibrin-targeted therapies for diseases driven by chronic inflammation. This funding will enable us to accelerate the development of our lead antibody program targeting inflammatory fibrin in neurodegenerative and retinal diseases. We look forward to advancing our first candidate, THN391, into clinical trials, and expect to announce key safety and proof of mechanism clinical data by the end of 2024," Michael Quigley, Therini Bio President and CEO.